Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.350
+0.080 (6.30%)
At close: Mar 9, 2026, 4:00 PM EDT
1.359
+0.009 (0.68%)
After-hours: Mar 9, 2026, 7:29 PM EDT
Akebia Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -5.35 | -69.41 | -51.93 | -94.23 | -282.02 | |
| Depreciation & Amortization | 1.27 | 37.5 | 37.63 | 37.7 | 37.97 | |
| Loss (Gain) From Sale of Assets | -0.17 | - | - | - | - | |
| Asset Writedown & Restructuring Costs | - | - | 0.78 | 8.77 | - | |
| Loss (Gain) From Sale of Investments | - | - | - | - | -0.02 | |
| Stock-Based Compensation | 11.28 | 7.78 | 9.32 | 17.85 | 22.74 | |
| Provision & Write-off of Bad Debts | 1.48 | 0.88 | - | - | - | |
| Other Operating Activities | 43.01 | 22.27 | 1.54 | -41.8 | 73.98 | |
| Change in Accounts Receivable | -14.14 | 4.05 | 0.99 | 11.3 | -24.03 | |
| Change in Inventory | -23.13 | -28.4 | -2.54 | 19.09 | -24.95 | |
| Change in Accounts Payable | 3.08 | -1.36 | -5.24 | 1.5 | -11.74 | |
| Change in Unearned Revenue | 2.68 | - | -3.74 | 4.65 | 1.82 | |
| Change in Other Net Operating Assets | 47.98 | -13.96 | -10.2 | -37.98 | -46.72 | |
| Operating Cash Flow | 67.99 | -40.66 | -23.38 | -73.15 | -252.97 | |
| Capital Expenditures | -0.29 | -0.03 | - | -0.11 | -0.06 | |
| Sale of Property, Plant & Equipment | 0.17 | - | - | - | - | |
| Sale (Purchase) of Intangibles | -7.81 | - | - | - | - | |
| Investment in Securities | - | - | - | - | 40 | |
| Investing Cash Flow | -7.93 | -0.03 | - | -0.11 | 39.94 | |
| Long-Term Debt Issued | 10 | 45 | - | - | - | |
| Long-Term Debt Repaid | -4.23 | -37.1 | -32 | -33 | - | |
| Net Debt Issued (Repaid) | 5.77 | 7.9 | -32 | -33 | - | |
| Issuance of Common Stock | 68.36 | 43.03 | 6.79 | 7.6 | 88.95 | |
| Other Financing Activities | -1.21 | -1.27 | - | 40 | 44.78 | |
| Financing Cash Flow | 72.93 | 49.66 | -25.21 | 14.6 | 133.73 | |
| Net Cash Flow | 132.99 | 8.97 | -48.59 | -58.67 | -79.29 | |
| Free Cash Flow | 67.7 | -40.69 | -23.38 | -73.27 | -253.02 | |
| Free Cash Flow Margin | 28.66% | -25.40% | -12.02% | -25.05% | -119.55% | |
| Free Cash Flow Per Share | 0.26 | -0.19 | -0.13 | -0.40 | -1.52 | |
| Cash Interest Paid | 6.08 | 5.04 | 6.06 | 6.76 | 9.63 | |
| Levered Free Cash Flow | 68.61 | 13.63 | 17.9 | -15.3 | -136.04 | |
| Unlevered Free Cash Flow | 83.73 | 25 | 21.67 | -5.5 | -123.53 | |
| Change in Working Capital | 16.47 | -39.68 | -20.73 | -1.44 | -105.61 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.